Adiponectin predicts subclinical atherosclerosis in nonalcoholic fatty liver disease
Adiponectin predicts subclinical atherosclerosis in nonalcoholic fatty liver disease
By Lorraine L. Janeczko
NEW YORK (Reuters Health) - In patients with nonalcoholic
fatty liver disease (NAFLD), adiponectin is a better predictor
of subclinical atherosclerosis than are liver function tests,
according to new research from Israel.
This suggests that adiponectin plays an active role in the
pathophysiology of vascular disease in this group, the authors
report online March 14 in Journal of the American Society of
Hypertension.
In patients with NAFLD, serum adiponectin levels were
significantly positively associated with indices of subclinical
atherosclerosis, such as pulse wave velocity (PWV) and aortic
augmentation index (AI), they write.
"This association was independent of age, sex, and blood
pressure level," said senior author Dr. Marina Shargorodsky of
Wolfson Medical Center in Holon and Sackler Faculty of Medicine
of Tel Aviv University, in an email to Reuters Health.
"Advanced liver disease is associated with paradoxically
increased adiponectin level, and adiponectin is associated with
increased arterial stiffness, which is considered a surrogate
for atherosclerotic disease as well as a predictor of
cardiovascular mortality," she said.
Asked whether serum adiponectin levels should be routinely
measured in patients with NAFLD, Dr. Shargorodsky replied,
"These findings may have implications for the long-term
cardiovascular health of NAFLD patients. The association between
adiponectin and impaired vascular stiffness, even before the
development of cardiovascular disease, obligates more aggressive
and earlier concomitant cardiovascular risk factor management in
this patient population."
"Moreover, follow up of circulating adiponectin level can
predict progression of the liver disease. Increased adiponectin
after initial decreased adiponectin levels could predict hepatic
fat decline with advanced fibrosis as well as increased
cardiovascular morbidity and mortality risk," she said.
Dr. Shargorodsky and her colleagues studied 52 patients with
NAFLD who were outpatients at one medical center and had a mean
age of 53.5 years.
The patients were screened by physical exam, complete blood
chemistry, complete blood count, urinalysis, and
electrocardiography.
Patients with a history of unstable angina, myocardial
infarction, cerebrovascular accident, or major surgery within
the past six months were excluded.
Subjects remained on all of their medications for up to
three months to prevent possible effects on the study variables,
and were instructed to consult the study physician if any change
in medical treatment was suggested by another physician.
PWV and AI were assessed using the SphygmoCor system.
The researchers found that adiponectin was significantly,
positively associated with PWV (r=0.348; p=0.011) and with AI
(r=0.467; p<0.0001).
They also found significant positive associations between
circulating adiponectin and aortic systolic pressure (r=0.295;
p=0.034) and aortic pulse pressure (r=0.309; p=0.026).
There was no association between arterial stiffness
parameters and liver function tests.
Dr. Sammy Saab of Ronald Reagan UCLA Medical Center and
David Geffen School of Medicine at UCLA in Los Angeles,
California, said in an email, "Fatty liver disease tends to
occur in the context of the metabolic syndrome with diabetes,
obesity, hypertension, and hypercholesterolemia. Many patients
with fatty liver are at increased risk for heart disease. Serum
adiponectin levels may identify those at highest risk so we can
intervene."
Dr. Saab, who was not involved in the study, advised against
routinely measuring serum adiponectin levels in patients with
NAFLD, saying, "More data are needed for us to know how to
interpret the results."
"This is an important study," Dr. Saab said, "but the
results are very preliminary. Additional research is necessary
to confirm the results. Serum adiponectin levels may not
completely be associated with severity of fatty liver."
"This study highlights the need for additional studies in
patients with fatty liver. Fatty liver is a huge public and
medical concern across the world. Treatment generally involves
treating the underlying process, which is the metabolic
syndrome," he said.
The authors advised that the precise mechanisms for these
vascular effects and the clinical impact of increased
adiponectin levels on cardiovascular outcomes in patients with
advanced NAFLD deserve further investigation.
SOURCE: http://bit.ly/1mYX29l
J Am Soc Hypertens 2014.
|